MedPath

A Long-term Study for Participants Previously Treated with Ciltacabtagene Autoleucel

Phase 3
Recruiting
Conditions
Multiple Myeloma
Registration Number
JPRN-jRCT2033220220
Lead Sponsor
Ei Fujikawa
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
228
Inclusion Criteria

Participants who have received at least one dose of cilta-cel in a Company-sponsored clinical study
- Participants who have provided informed consent for this study

Exclusion Criteria

N/A

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath